Novo Nordisk

We're dedicated to championing long-term health. Stay tuned for news and the latest in innovation 💙 Community guide 👇

[Novo Nordisk @novonordisk]

#PRESS: Prescriptions of our obesity pill surpass 3 million since launch.

The majority of new pill prescriptions are for people new to GLP-1 therapy, bringing obesity medicine to many previously untreated.

Learn more in the press release here: https://t.co/sk0CfjWoF8

[Novo Nordisk @novonordisk]

IT Security Incident at Novo Nordisk

Learn more in the press release here: https://t.co/iGoHJnjbRi

[Novo Nordisk @novonordisk]

#PRESS: Results from our phase 3 trials presented at the ADA Scientific Sessions showed that our first amylin-based investigational treatment for metabolic diseases shows promising, consistent reductions in blood sugar and weight across various stages of type 2 diabetes.

With these findings, the investigational treatment has the potential to be a first-in-class amylin and GLP-1 combination therapy for people with type 2 diabetes.

Learn more in the press release here: https://t.co/OA86T8Vlb0

[Novo Nordisk @novonordisk]

#PRESS: We’re presenting new analyses at the ADA 2026 Scientific Sessions, exploring our obesity treatment’s impact across a wide range of obesity-related and cardiometabolic conditions.

Findings from four different trials examine outcomes in obstructive sleep apnea, asthma-related adverse events, cardiometabolic risk factors, and other weight-related complications.

Learn more in the press release here: https://t.co/dDOhx8Ow44

[Novo Nordisk @novonordisk]

#PRESS: New real-world evidence presented at the ADA Scientific Sessions suggests adults with type 2 diabetes who escalated to an available higher once-weekly injectable semaglutide dose were as likely to achieve blood sugar goals and more likely to achieve meaningful weight loss compared to switching to another therapy.

Learn more in the press release here:
https://t.co/YaTllbAVYT

[Novo Nordisk @novonordisk]

@GreenJeanASSET I am sorry to hear that. I understand your frustration and let me see if I can follow-up. Have you received any information regarding your voucher you can share with me? I can try and contct the US tesam's patient support and ask them for a status update.

[Novo Nordisk @novonordisk]

@GreenJeanASSET Thank you for letting me know. I have filed your case with my Patient Safety colleagues. I hope it is ok to message you here if I get any follow-up questions from them. All the best, Scott, Novo Nordisk

[Novo Nordisk @novonordisk]

We are presenting phase two clinical data at the ADA Scientific Sessions showcasing investigational zenagamtide's ability to significantly reduce blood sugar and body weight in adults with type 2 diabetes.

Based on these results, zenagamtide will advance into phase three clinical trials.

Learn more in the press release here: https://t.co/OJ1LbCqCX7

[Novo Nordisk @novonordisk]

I am sorry to hear about this. Please contact your doctor if you feel ill. If you are in the USA, please call [phone]. As your post contains safety information, we are required by law to report it to the health authorities. Could you share your contact detials in a PM?
https://t.co/vxrbW3Av2a

[Novo Nordisk @novonordisk]

#PRESS: Our GLP-1 pill for the treatment of overweight or obesity launches in the United Arab Emirates as we expand global access to obesity care.

Learn more in the press release here: https://t.co/oN4gNC9uoE

[Novo Nordisk @novonordisk]

Hi,Thanks for your question! We have not announced any plans outside the UAE and US regions. If you are interested, you can subscribe here for latest news: https://t.co/P0tnX4TXvs.

You can also reach out to your local Novo Nordisk office for any questions: https://t.co/yxHKE1QoVF

[Novo Nordisk @novonordisk]

@AvSevgii I am sorry to hear about this. Please contact your doctor if you feel ill.

As your post contains so-called safety information, we are required by law to report it to the health authorities. Your data will be handled as per applicable regulations.

[Novo Nordisk @novonordisk]

#PRESS: New data from our cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans.

From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide.

Learn more in the press release here: https://t.co/KkpwZn94py

[Novo Nordisk @novonordisk]

We’re presenting new findings from our real-world-evidence study, POSEIDON, at the European Atherosclerosis Society (EAS) Congress. Our landmark study shows that 2 in 5 people with heart disease have CV inflammation, which increases the risk of heart attack or stroke.

Learn more in the press release here: https://t.co/zbXUHR6XwP

[Novo Nordisk @novonordisk]

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) recommends EU approval of our high-dose obesity injection in a single-dose pen, providing up to 20.7% mean weight loss.

Learn more in our company announcement here: https://t.co/gvJOGOQlYT

[Novo Nordisk @novonordisk]

@CecilRocca Hi Ceci. Thanks for reaching out. I don't think that is our site. Which information are you looking for? 🤗

[Novo Nordisk @novonordisk]

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of our GLP-1 pill for the treatment of obesity in the European Union (EU), making it one step closer to becoming available for people with overweight or obesity in the EU.

Learn more in our company announcement here: https://t.co/mNIra4WgRN

[Novo Nordisk @novonordisk]

@MzDickson Hello, thanks for reaching out. We would like to help by connecting you to our customer care team. You may call them at 1-800-727-6500.

[Novo Nordisk @novonordisk]

@HINGORANISS I am sorry to hear about this. Please contact your doctor if you feel ill.

As your post contains so-called safety information, we are required by law to report it to the health authorities. Your data will be handled as per applicable regulations.